enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of “Moderate Buy” by Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $23.2857.

ENGN has been the topic of a number of recent research reports. Citizens Jmp raised their price objective on shares of enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 12th. Citigroup restated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Oppenheimer reiterated an “outperform” rating and set a $33.00 price target (up from $30.00) on shares of enGene in a research note on Wednesday, November 12th. UBS Group boosted their price objective on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a report on Wednesday, November 12th. Finally, Raymond James Financial upgraded enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price on the stock in a report on Tuesday, November 11th.

Institutional Trading of enGene

Institutional investors have recently made changes to their positions in the company. Affinity Asset Advisors LLC bought a new position in shares of enGene during the 2nd quarter worth approximately $280,000. Elmind Capital LP purchased a new stake in shares of enGene during the fourth quarter valued at approximately $1,896,000. Eversept Partners LP bought a new stake in enGene during the fourth quarter worth $4,116,000. Cormorant Asset Management LP boosted its position in enGene by 72.1% in the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after purchasing an additional 1,676,405 shares during the last quarter. Finally, Omega Fund Management LLC boosted its position in enGene by 66.5% in the fourth quarter. Omega Fund Management LLC now owns 876,357 shares of the company’s stock worth $7,914,000 after purchasing an additional 350,000 shares during the last quarter. Institutional investors own 64.16% of the company’s stock.

enGene Trading Up 0.8%

Shares of enGene stock opened at $10.11 on Friday. The stock has a market capitalization of $677.27 million, a PE ratio of -4.41 and a beta of -0.29. enGene has a 52 week low of $2.65 and a 52 week high of $12.25. The stock has a 50 day moving average price of $9.57 and a two-hundred day moving average price of $7.84. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30.

enGene (NASDAQ:ENGN) last issued its earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). As a group, equities analysts anticipate that enGene will post -1.56 earnings per share for the current fiscal year.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.